Cover Image

LORDs: Locally Optimal Restricted Designs for Phase I/II Dose-Finding Studies

Fuente: arXiv

Saved in:

Bibliographic Details
Main Authors:	Sverdlov, Oleksandr, Ryeznik, Yevgen, Wong, Weng Kee
Format:	Preprint
Published:	2025
Subjects:	Methodology
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Incertus.jl -- The Julia Lego Blocks for Randomized Clinical Trial Designs
by: Ryeznik, Yevgen, et al.
Published: (2024)

Randomization Restrictions: Their Impact on Type I Error When Experimenting with Finite Populations
by: Chipman, Jonathan J., et al.
Published: (2025)

Failure of Optimal Design Theory? A Case Study in Toxicology Using Sequential Robust Optimal Design Framework
by: Cui, Elvis Han, et al.
Published: (2025)

Understanding an impact of patient enrollment pattern on predictability of central (unstratified) randomization in a multi‐center clinical trial
by: Johannes Krisam, et al.
Published: (2024)

Estimands for Randomized Discontinuation Designs in Oncology
by: Mukherjee, Ayon, et al.
Published: (2025)

Randomization-based Inference for MCP-Mod
by: Pin, Lukas, et al.
Published: (2024)

Precision Dose-Finding Design for Phase I Oncology Trials by Integrating Pharmacology Data
by: Lee, Kyong Ju, et al.
Published: (2025)

A Likelihood Perspective on Dose-Finding Study Designs in Oncology
by: Zhang, Zhiwei
Published: (2023)

Defining Utility as a Measure of Preference Under Uncertainty in Phase I-II Oncology Dose Finding Trials
by: Hall, Andrew, et al.
Published: (2025)

Mathematical programming tools for randomization purposes in small two-arm clinical trials: A case study with real data
by: Vazquez, Alan R., et al.
Published: (2024)

Bayesian Optimization for Identification of Optimal Biological Dose Combinations in Personalized Dose-Finding Trials
by: Willard, James, et al.
Published: (2024)

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology
by: Sun, Hao, et al.
Published: (2024)

BOIN Designs for Dose Escalation With Selected Dose Combinations in Oncology Phase I Trials
by: Chen, Yuxuan, et al.
Published: (2026)

Dual-criterion Dose Finding Designs Based on Dose-Limiting Toxicity and Tolerability
by: Yang, Yunlong, et al.
Published: (2024)

An Adaptive Phase II Trial Design for Dose Selection and Addition in Microfilarial Infections
by: Zehetmayer, Sonja, et al.
Published: (2026)

Single and multi-objective optimal designs for group testing experiments with a focus on screening for an infectious disease
by: Yeh, Chi-Kuang, et al.
Published: (2025)

A Seamless Phase II/III Design with Dose Optimization for Oncology Drug Development
by: Li, Yuhan, et al.
Published: (2024)

ROSE: Randomized Optimal Selection Design for Dose Optimization
by: Wang, Shuqi, et al.
Published: (2025)

BOP2-TE: Bayesian Optimal Phase 2 Design for Jointly Monitoring Efficacy and Toxicity with Application to Dose Optimization
by: Chen, Kai, et al.
Published: (2024)

Adaptive Weighting for Time-to-Event Continual Reassessment Method: Improving Safety in Phase I Dose-Finding Through Data-Driven Delay Distribution Estimation
by: Amevor, Robert, et al.
Published: (2026)

Bayesian Optimization for Personalized Dose-Finding Trials with Combination Therapies
by: Willard, James, et al.
Published: (2023)

A Comparative Evaluation of Bayesian Model-Assisted Two-Stage Designs for Phase I/II Clinical Trials
by: Sun, Hao, et al.
Published: (2025)

TITE-STEIN: Time-to-event Simple Toxicity and Efficacy Interval Design to Accelerate Phase I/II Trials
by: Sun, Hao, et al.
Published: (2025)

Optimal sequential two-stage Bayes Factor Design for two-arm clinical Phase II Trials with binary Endpoints
by: Kelter, Riko
Published: (2026)

Utility-Based Dose Optimization Approaches for Multiple-Dose Randomized Trial Designs Accounting for Multiple Endpoints
by: DAngelo, Gina, et al.
Published: (2025)

Studying Optimal Designs for Multivariate Crossover Trials
by: Niphadkar, Shubham, et al.
Published: (2025)

Optimal Watermark Generation under Type I and Type II Errors
by: He, Hengzhi, et al.
Published: (2025)

Causal Effect Estimation on Restricted Mean Survival Time in Case-Cohort Studies via a Matching Design
by: Ni, Andy, et al.
Published: (2026)

Bridging the Gap Between Design and Analysis: Randomization Inference and Sensitivity Analysis for Matched Observational Studies with Treatment Doses
by: Zhang, Jeffrey, et al.
Published: (2024)

Rate Optimality and Phase Transition for User-Level Local Differential Privacy
by: Kent, Alexander, et al.
Published: (2024)

BE-BOIN: A Dose Optimization Design Accommodating Backfill and Late-Onset Toxicity
by: Chen, Kai, et al.
Published: (2025)

Seamless Phase I--II Cancer Clinical Trials Using Kernel-Based Covariate Similarity
by: Makino, Kana, et al.
Published: (2025)

A Bayesian Treatment Selection Design for Phase II Randomised Cancer Clinical Trials
by: Komaki, Moka, et al.
Published: (2025)

ROMI: A Randomized Two-Stage Basket Trial Design to Optimize Doses for Multiple Indications
by: Wang, Shuqi, et al.
Published: (2024)

Beyond Fixed Restriction Time: Adaptive Restricted Mean Survival Time Methods in Clinical Trials
by: Sun, Jinghao, et al.
Published: (2025)

Estimands for Early Phase Dose Optimization Trials in Oncology
by: Mukherjee, Ayon, et al.
Published: (2025)

Design and Analysis Considerations for Causal Inference under Two-Phase Sampling in Observational Studies
by: Harada, Kazuharu, et al.
Published: (2025)

Optimal Designs for Gamma Degradation Tests
by: Tung, Hung-Ping, et al.
Published: (2025)

Universally Optimal Multivariate Crossover Designs
by: Niphadkar, Shubham, et al.
Published: (2023)

Optimal Designs for Two-Stage Inference
by: Stallrich, Jonathan W., et al.
Published: (2023)